Vaccine Adjuvants Market by Product (Emulsions, Pathogen, Saponin, Particulate), Route of administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Type ( Human vaccine , Veterinary vaccine) - Global Forecast to 2028

Vaccine Adjuvants Market by Product (Emulsions, Pathogen, Saponin, Particulate), Route of administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Type ( Human vaccine , Veterinary vaccine) - Global Forecast to 2028



The global vaccine adjuvants market size is projected to reach USD 1.2 billion by 2028 from USD 0.8 billion in 2023, at a CAGR of 6.9% during the forecast period. Factors such as as the rising prevalence of infectious diseases, increasing number of vaccines under clinical trials, and increasing focus on immunization programs are likely to have positive impact on the market growth.

“The adjuvant emulsions segment held the dominant share in the vaccine adjuvants market”

Based on product, the global vaccine adjuvants market is segmented into pathogen component, adjuvant emulsions, particulate adjuvants, saponin-based adjuvants and other adjuvants. The adjuvant emulsions segment held a dominant share in the market in 2022. Extensive use of adjuvant emulsions in COVID-19 & other infectious diseases and the rising prevalence of contagious diseases are likely to have positive impact on the growth of the market.

“infectious disease segment accounted for the largest share of the disease type segment in 2022.”

Based on disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer and other diseases. In 2022, the infectious disease segment accounted for the largest share of the vaccine adjuvants market. The segment held the dominant share in the market owing to various factors such as increasing prevalence of infectious diseases and the rising demand for new adjuvanted vaccines for infectious diseases such as influenza.

“Asia Pacific region is likely to grow at a faster pace.”

The vaccine adjuvants market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The increasing demand for vaccine adjuvants from China, India, and Japan due to presence of prominent players engaged in vaccine development, supports market growth in the Asia Pacific. Furthermore rising cancer incidence and government initiatives for vaccine development and immunization are some of the elements anticipated to account for positive impact on the market growth.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 80%, and Demand Side - 20%

By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%

By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%

List of Companies Profiled in the Report:

Dynavax Technologies (US)

Croda International plc (UK)

GSK plc (UK)

Seppic (France)

Novavax (US)

SPI pharma ( subsidiary of Associated British Foods plc ) (UK)

Agenus Inc. (US)

Phibro Animal Health Corporation (US)

Aurorium (Vertellus) (US)

Merck KGaA (Germany)

Vaxine Pty Ltd. (Australia)

Hawaii Biotech Inc. (US)

CSL Limited (Australia)

OZ Biosciences (US)

InvivoGen (US)

Allergy Therapeutics (UK)

EuBiologics Co., Ltd. (South Korea)

Pacific GeneTech Limited (US)

Riboxx GmbH (Germany)

CaPtivate Pharmaceuticals LLC (US)

Creative Diagnostics (US)

LiteVax BV (Netherlands)

Mukta Industries (India)

Oncovir, Inc. (US)

TiterMax USA, Inc. (US).

Research Coverage:

This report provides a detailed picture of the vaccine adjuvants market. It aims at estimating the size and future growth potential of the market across different segments, such as product, route of administration, disease type, application, type and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccine adjuvants market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Rising prevalence of infectious diseases, increasing collaborations and partnerships among market players for adjuvanted vaccines development, Growing product pipeline, Growing focus on immunization programs), restraints ( Side effects and high toxicity of adjuvants), opportunities (Growing funding for vaccines and increasing infectious disease research activities, development of plant-based vaccine adjuvants) and challenges (Concerns regarding animal-sourced vaccine adjuvants and limitations on shark fishing) are influencing the growth of vaccine adjuvants market.

Product Development/Innovation: Detailed insights on newly launched products of the vaccine adjuvants market.

Market Development: Comprehensive information about lucrative markets – the report analyses the vaccine adjuvants market across varied regions.

Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the vaccine adjuvants market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Dynavax Technologies (US), Croda International plc (UK), GSK plc (UK), Seppic (France) , Novavax (US), SPI pharma (US), Agenus Inc. (US), Phibro Animal Health Corporation (US) and among others in the vaccine adjuvants market.


  • INTRODUCTION
    • STUDY OBJECTIVES
    • MARKET DEFINITION
      • INCLUSIONS & EXCLUSIONS
    • MARKET SCOPE
      • MARKETS COVERED
      • YEARS CONSIDERED
      • CURRENCY CONSIDERED
    • RESEARCH LIMITATIONS
    • STAKEHOLDERS
    • SUMMARY OF CHANGES
    • RECESSION IMPACT
  • RESEARCH METHODOLOGY
    • RESEARCH APPROACH
      • PRIMARY RESEARCH
      • SECONDARY DATA
    • MARKET SIZE ESTIMATION
      • INSIGHTS FROM PRIMARIES
      • SEGMENT ASSESSMENT (BY PRODUCT, ROUTE OF ADMINISTRATION, DISEASE TYPE, APPLICATION, TYPE, AND REGION)
    • GROWTH RATE ASSUMPTIONS
    • MARKET BREAKDOWN AND DATA TRIANGULATION
    • STUDY ASSUMPTIONS
    • RISK ANALYSIS
    • RECESSION IMPACT ANALYSIS
      • Table GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)
  • EXECUTIVE SUMMARY
  • PREMIUM INSIGHTS
    • VACCINE ADJUVANTS MARKET OVERVIEW
    • NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT AND COUNTRY (2022)
    • VACCINE ADJUVANTS MARKET SHARE, BY PRODUCT, 2023 VS. 2028
    • VACCINE ADJUVANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • MARKET OVERVIEW
    • INTRODUCTION
    • MARKET DYNAMICS
      • Table VACCINE ADJUVANTS MARKET: IMPACT ANALYSIS
      • DRIVERS
      • RESTRAINTS
      • OPPORTUNITIES
        • Table NIH FUNDING FOR VACCINE RESEARCH, 2019-2023 (USD MILLION)
      • CHALLENGES
    • TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • PRICING ANALYSIS
      • AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS
        • Table AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (TOP 5)
      • AVERAGE SELLING PRICE, BY PRODUCT TYPE
        • Table AVERAGE SELLING PRICE OF ADJUVANT EMULSIONS
        • Table AVERAGE SELLING PRICE OF PARTICULATE ADJUVANTS
        • Table AVERAGE SELLING PRICE OF SAPONIN-BASED ADJUVANTS
    • TECHNOLOGY ANALYSIS
    • VALUE CHAIN ANALYSIS
    • ECOSYSTEM ANALYSIS
      • Table SUPPLY CHAIN ECOSYSTEM
    • KEY CONFERENCES & EVENTS IN 2023-2024
      • Table VACCINE ADJUVANTS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
    • REGULATORY ANALYSIS
      • REGULATORY LANDSCAPE FOR VACCINE ADJUVANTS
      • REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
        • Table NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
        • Table EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
        • Table ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
        • Table LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
        • Table MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • PORTER'S FIVE FORCES ANALYSIS
      • Table VACCINE ADJUVANTS MARKET: PORTER'S FIVE FORCES ANALYSIS
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTES
      • BARGAINING POWER OF SUPPLIERS
      • BARGAINING POWER OF BUYERS
      • DEGREE OF COMPETITION
        • Table VACCINE ADJUVANTS MARKET: INDICATIVE LIST OF PATENTS
    • KEY STAKEHOLDERS & BUYING CRITERIA
      • KEY STAKEHOLDERS IN BUYING PROCESS
      • BUYING CRITERIA FOR VACCINE ADJUVANT PRODUCTS
  • VACCINE ADJUVANTS MARKET, BY PRODUCT
    • INTRODUCTION
      • Table VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • ADJUVANT EMULSIONS
      • EXTENSIVE USE OF ADJUVANT EMULSIONS IN HUMAN VACCINES TO DRIVE GROWTH
        • Table ADJUVANT EMULSIONS MARKET, BY REGION, 2021-2028 (USD MILLION)
        • Table NORTH AMERICA: ADJUVANT EMULSIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table EUROPE: ADJUVANT EMULSIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table ASIA PACIFIC: ADJUVANT EMULSIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • PATHOGEN COMPONENTS
      • INCREASING NUMBER OF PROMINENT PLAYERS OFFERING BACTERIA-DERIVED ADJUVANTS TO DRIVE GROWTH
        • Table PATHOGEN COMPONENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
        • Table NORTH AMERICA: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table EUROPE: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table ASIA PACIFIC: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • SAPONIN-BASED ADJUVANTS
      • INCREASING USE OF SAPONIN-BASED ADJUVANTS TO SUPPORT MARKET GROWTH
        • Table SAPONIN-BASED ADJUVANTS MARKET, BY REGION, 2021-2028 (USD MILLION)
        • Table NORTH AMERICA: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table EUROPE: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table ASIA PACIFIC: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • PARTICULATE ADJUVANTS
      • GROWING DEMAND FOR MINERAL-BASED ADJUVANTS TO BOOST MARKET
        • Table PARTICULATE ADJUVANTS MARKET, BY REGION, 2021-2028 (USD MILLION)
        • Table NORTH AMERICA: PARTICULATE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table EUROPE: PARTICULATE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table ASIA PACIFIC: PARTICULATE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • OTHER ADJUVANTS
      • Table OTHER VACCINE ADJUVANTS MARKET, BY REGION, 2021-2028 (USD MILLION)
      • Table NORTH AMERICA: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • Table EUROPE: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • Table ASIA PACIFIC: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION
    • INTRODUCTION
      • Table VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • INTRAMUSCULAR
      • BETTER ABSORPTION RATE ASSOCIATED WITH INTRAMUSCULAR ADMINISTRATION TO DRIVE MARKET GROWTH
        • Table ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR ADMINISTRATION
        • Table VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY REGION, 2021-2028 (USD MILLION)
        • Table NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table EUROPE: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • SUBCUTANEOUS
      • FREQUENT USE OF SUBCUTANEOUS ROUTE OF ADMINISTRATION TO BOOST MARKET
        • Table ADVANTAGES AND DISADVANTAGES OF SUBCUTANEOUS ADMINISTRATION
        • Table VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY REGION, 2021-2028 (USD MILLION)
        • Table NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table EUROPE: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • OTHER ROUTES OF ADMINISTRATION
      • Table VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2021-2028 (USD MILLION)
      • Table NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
      • Table EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
      • Table ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • VACCINE ADJUVANTS MARKET, BY DISEASE TYPE
    • INTRODUCTION
      • Table VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • INFECTIOUS DISEASES
      • GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
        • Table VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
        • Table NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table EUROPE: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • CANCER
      • INCREASING DEMAND FOR NOVEL CANCER VACCINES TO SUPPORT MARKET GROWTH
        • Table VACCINE ADJUVANTS MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION)
        • Table NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table EUROPE: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • OTHER DISEASES
      • Table VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY REGION, 2021-2028 (USD MILLION)
      • Table NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
      • Table EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
      • Table ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • VACCINE ADJUVANTS MARKET, BY APPLICATION
    • INTRODUCTION
      • Table VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • RESEARCH APPLICATIONS
      • EXTENSIVE R&D FOR DEVELOPMENT OF VACCINE ADJUVANTS TO DRIVE MARKET
        • Table VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
        • Table NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table EUROPE: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • COMMERCIAL APPLICATIONS
      • GROWING USE OF VACCINE ADJUVANTS FOR COMMERCIAL APPLICATIONS TO SUPPORT MARKET GROWTH
        • Table VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
        • Table NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table EUROPE: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
  • VACCINE ADJUVANTS MARKET, BY TYPE
    • INTRODUCTION
      • Table VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • HUMAN VACCINE ADJUVANTS
      • INCREASING PARTNERSHIPS FOR DEVELOPMENT OF HUMAN VACCINE ADJUVANTS TO AID MARKET GROWTH
        • Table HUMAN VACCINE ADJUVANTS MARKET, BY REGION, 2021-2028 (USD MILLION)
        • Table NORTH AMERICA: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table EUROPE: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table ASIA PACIFIC: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • VETERINARY VACCINE ADJUVANTS
      • INCREASING USE OF ADJUVANTED VACCINES AS PREVENTIVE CARE IN ANIMAL HEALTH TO DRIVE MARKET
        • Table VETERINARY VACCINE ADJUVANTS MARKET, BY REGION, 2021-2028 (USD MILLION)
        • Table NORTH AMERICA: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table EUROPE: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
        • Table ASIA PACIFIC: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • VACCINE ADJUVANTS MARKET, BY REGION
    • INTRODUCTION
      • Table VACCINE ADJUVANTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • NORTH AMERICA
      • Table NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • Table NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
      • Table NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
      • Table NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
      • Table NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
      • Table NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
      • US
        • Table US: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
        • Table US: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
        • Table US: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
        • Table US: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
        • Table US: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
      • CANADA
        • Table CANADA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
        • Table CANADA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
        • Table CANADA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
        • Table CANADA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
        • Table CANADA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
      • NORTH AMERICA: RECESSION IMPACT
    • EUROPE
      • Table EUROPE: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • Table EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
      • Table EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
      • Table EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
      • Table EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
      • Table EUROPE: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
      • GERMANY
        • Table GERMANY: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
        • Table GERMANY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
        • Table GERMANY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
        • Table GERMANY: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
        • Table GERMANY: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
      • UK
        • Table UK: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
        • Table UK: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
        • Table UK: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
        • Table UK: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
        • Table UK: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
      • FRANCE
        • Table FRANCE: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
        • Table FRANCE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
        • Table FRANCE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
        • Table FRANCE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
        • Table FRANCE: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
      • ITALY
        • Table ITALY: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
        • Table ITALY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
        • Table ITALY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
        • Table ITALY: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
        • Table ITALY: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
      • SPAIN
        • Table SPAIN: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
        • Table SPAIN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
        • Table SPAIN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
        • Table SPAIN: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
        • Table SPAIN: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
      • REST OF EUROPE
        • Table REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
        • Table REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
        • Table REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
        • Table REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
        • Table REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
      • EUROPE: RECESSION IMPACT
    • ASIA PACIFIC
      • Table ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • Table ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
      • Table ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
      • Table ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
      • Table ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
      • Table ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
      • CHINA
        • Table CHINA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
        • Table CHINA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
        • Table CHINA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
        • Table CHINA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
        • Table CHINA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
      • JAPAN
        • Table JAPAN: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
        • Table JAPAN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
        • Table JAPAN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
        • Table JAPAN: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
        • Table JAPAN: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
      • INDIA
        • Table INDIA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
        • Table INDIA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
        • Table INDIA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
        • Table INDIA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
        • Table INDIA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
      • REST OF ASIA PACIFIC
        • Table REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
        • Table REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
        • Table REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
        • Table REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
        • Table REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
      • ASIA PACIFIC: RECESSION IMPACT
    • LATIN AMERICA
      • GROWING PHARMACEUTICAL & BIOTECHNOLOGY RESEARCH TO DRIVE MARKET GROWTH
      • LATIN AMERICA: RECESSION IMPACT
        • Table LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
        • Table LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
        • Table LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
        • Table LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
        • Table LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • MIDDLE EAST & AFRICA
      • INCREASING FUNDING AND GRANTS FOR VACCINE DEVELOPMENT TO SUPPORT MARKET GROWTH
      • MIDDLE EAST & AFRICA: RECESSION IMPACT
        • Table MIDDLE EAST & AFRICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
        • Table MIDDLE EAST & AFRICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
        • Table MIDDLE EAST & AFRICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
        • Table MIDDLE EAST & AFRICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
        • Table MIDDLE EAST & AFRICA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • COMPETITIVE LANDSCAPE
    • INTRODUCTION
    • STRATEGIES ADOPTED BY KEY PLAYERS
    • REVENUE SHARE ANALYSIS
    • MARKET SHARE ANALYSIS
      • Table VACCINE ADJUVANTS MARKET: DEGREE OF COMPETITION
    • COMPANY EVALUATION MATRIX
      • STARS
      • EMERGING LEADERS
      • PERVASIVE PLAYERS
      • PARTICIPANTS
      • COMPANY FOOTPRINT
        • Table VACCINE ADJUVANTS MARKET: COMPANY PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS
      • REGIONAL FOOTPRINT OF TOP 25 COMPANIES
        • Table VACCINE ADJUVANTS MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
    • START-UP/SME EVALUATION MATRIX
      • PROGRESSIVE COMPANIES
      • STARTING BLOCKS
      • RESPONSIVE COMPANIES
      • DYNAMIC COMPANIES
    • COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
      • Table PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET
      • Table VACCINE ADJUVANTS MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS
    • COMPETITIVE SCENARIO AND TRENDS
      • PRODUCT LAUNCHES & APPROVALS
        • Table VACCINE ADJUVANTS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JULY 2023
      • DEALS
        • Table VACCINE ADJUVANTS MARKET: DEALS, JANUARY 2021-JULY 2023
      • OTHER DEVELOPMENTS
        • Table VACCINE ADJUVANTS MARKET: OTHER DEVELOPMENTS, JANUARY 2021-JULY 2023
  • COMPANY PROFILES
    • KEY MARKET PLAYERS
      • DYNAVAX TECHNOLOGIES
        • Table DYNAVAX TECHNOLOGIES: BUSINESS OVERVIEW
      • CRODA INTERNATIONAL PLC
        • Table CRODA INTERNATIONAL PLC: BUSINESS OVERVIEW
      • GSK PLC
        • Table GSK PLC: BUSINESS OVERVIEW
      • SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP)
        • Table SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP): BUSINESS OVERVIEW
      • NOVAVAX
        • Table NOVAVAX: BUSINESS OVERVIEW
      • SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC)
        • Table SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC): BUSINESS OVERVIEW
      • AGENUS INC.
        • Table AGENUS INC.: BUSINESS OVERVIEW
      • PHIBRO ANIMAL HEALTH CORPORATION
        • Table PHIBRO ANIMAL HEALTH CORPORATION: BUSINESS OVERVIEW
      • AURORIUM (FORMERLY VERTELLUS)
        • Table AURORIUM (FORMERLY VERTELLUS): BUSINESS OVERVIEW
      • MERCK KGAA
        • Table MERCK KGAA: BUSINESS OVERVIEW
      • VAXINE PTY LTD.
        • Table VAXINE PTY LTD.: BUSINESS OVERVIEW
      • HAWAII BIOTECH INC.
        • Table HAWAII BIOTECH INC.: BUSINESS OVERVIEW
      • CSL LIMITED
        • Table CSL LIMITED: BUSINESS OVERVIEW
      • OZ BIOSCIENCES
        • Table OZ BIOSCIENCES: BUSINESS OVERVIEW
      • INVIVOGEN
        • Table INVIVOGEN: BUSINESS OVERVIEW
      • ALLERGY THERAPEUTICS
        • Table ALLERGY THERAPEUTICS: BUSINESS OVERVIEW
      • EUBIOLOGICS CO., LTD.
        • Table EUBIOLOGICS CO., LTD.: BUSINESS OVERVIEW
      • PACIFIC GENETECH LIMITED
        • Table PACIFIC GENETECH LIMITED: BUSINESS OVERVIEW
      • RIBOXX GMBH
        • Table RIBOXX GMBH: BUSINESS OVERVIEW
      • CAPTIVATE PHARMACEUTICALS LLC
        • Table CAPTIVATE PHARMACEUTICALS LLC: BUSINESS OVERVIEW
    • OTHER PLAYERS
      • CREATIVE DIAGNOSTICS
      • LITEVAX B.V.
      • MUKTA INDUSTRIES
      • ONCOVIR, INC.
      • TITERMAX USA, INC.
  • APPENDIX
    • DISCUSSION GUIDE
    • KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
    • CUSTOMIZATION OPTIONS
    • RELATED REPORTS
    • AUTHOR DETAILS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings